115977-42-9

Basic information

• Product Name: (1R,2S)-2-(4-nitrophenyl)cyclopropanamine
• CAS NO: 115977-42-9
• Molecular Formula: C₉H₁₀N₂O₂
• Molecular Weight: 178.1879
• Mol File: 115977-42-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 316.7°C at 760 mmHg
• Flash Point: 145.3°C
• Density: 1.302g/cm³
• Vapor Pressure: 0.000403mmHg at 25°C
• Refractive Index: 1.625
• CAS DataBase Reference: (1R,2S)-2-(4-nitrophenyl)cyclopropanamine(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,2S)-2-(4-nitrophenyl)cyclopropanamine(115977-42-9)
• EPA Substance Registry System: (1R,2S)-2-(4-nitrophenyl)cyclopropanamine(115977-42-9)

Safety Data

• Hazardous Substances Data: 115977-42-9(Hazardous Substances Data)

Usage

Description

(1R,2S)-2-(4-nitrophenyl)cyclopropanamine is a chiral cyclopropanamine derivative with a molecular formula of C9H11N2O2 and a molecular weight of 177.2 g/mol. It features a 4-nitrophenyl group attached to the cyclopropane ring and possesses two stereocenters, designated as (1R,2S). (1R,2S)-2-(4-nitrophenyl)cyclopropanamine belongs to the family of cyclopropanamines, which are three-membered cyclic amines, and holds potential for applications in medicinal chemistry, particularly in drug development and pharmaceuticals.

Uses

Used in Medicinal Chemistry:
(1R,2S)-2-(4-nitrophenyl)cyclopropanamine is used as a compound of interest in medicinal chemistry for its potential applications in the development of new drugs and pharmaceuticals. Its unique chemical structure and properties make it a promising candidate for further research and study.
Used in Organic Chemistry Research:
In the field of organic chemistry, (1R,2S)-2-(4-nitrophenyl)cyclopropanamine serves as a subject of interest for its chemical properties and biological activities, contributing to the advancement of knowledge and potential applications in various chemical processes and reactions.
Used in Pharmacology:
(1R,2S)-2-(4-nitrophenyl)cyclopropanamine is utilized in pharmacology for its potential role in the discovery and development of novel therapeutic agents. Its unique stereochemistry and molecular structure may offer new avenues for targeting specific biological pathways and mechanisms, leading to the creation of more effective treatments and medications.

Upstream product

• 16633-46-8 trans-2-(p-Nitrophenyl-)cyclopropanecarboxylic acid 

Relevant articles and documents

Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2

LSD1 and LSD2 histone demethylases are implicated in a number of physiological and pathological processes, ranging from tumorigenesis to herpes virus infection. A comprehensive structural, biochemical, and cellular study is presented here to probe the potential of these enzymes for epigenetic therapies. This approach employs tranylcypromine as a chemical scaffold for the design of novel demethylase inhibitors. This drug is a clinically validated antidepressant known to target monoamine oxidases A and B. These two flavoenzymes are structurally related to LSD1 and LSD2. Mechanistic and crystallographic studies of tranylcypromine inhibition reveal a lack of selectivity and differing covalent modifications of the FAD cofactor depending on the enantiomeric form. These findings are pharmacologically relevant, since tranylcypromine is currently administered as a racemic mixture. A large set of tranylcypromine analogues were synthesized and screened for inhibitory activities. We found that the common evolutionary origin of LSD and MAO enzymes, despite their unrelated functions and substrate specificities, is reflected in related ligand-binding properties. A few compounds with partial enzyme selectivity were identified. The biological activity of one of these new inhibitors was evaluated with a cellular model of acute promyelocytic leukemia chosen since its pathogenesis includes aberrant activities of several chromatin modifiers. Marked effects on cell differentiation and an unprecedented synergistic activity with antileukemia drugs were observed. These data demonstrate that these LSD1/2 inhibitors are of potential relevance for the treatment of promyelocytic leukemia and, more generally, as tools to alter chromatin state with promise of a block of tumor progression.